Japan Tobacco Inc.

Yoshitomi Pharmaceutical Industries, Ltd.

Masanori Shindo

Takashi Nakagawa

Takeshi Nakamura

Kenji Chiba

Tetsuya Tahara

Teruhiko Inoue

Minoru Moriwaki

Shunichi Manabe

Taku Ikenogami

Yuko Shinagawa

Naoki Ogawa

Toshihiro Kiguchi

Yuki Soejima

Yoshihisa Koga

Kenji Fukuda

A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.

CaSR antagonist

The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.

Therapeutic agent for osteoporosis and triazepine compound

A therapeutic agent for osteoporosis, comprising an azepine compound of the formula ##STR1## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.

Therapeutic agent for osteoporosis and diazepine compound

Growing community of inventors

Takatsuki, Japan

Masanori Shindo